

Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease

T. LIND*, L. RYDBERG*, A. KYLEBÄCK*, A. JONSSON*, T. ANDERSSON†, G. HASSELGREN‡, J. HOLMBERG‡ & K. RÖHSS‡

*Department of Surgery, Kärnsjukhuset, Skövde, Sweden; †AstraZeneca LP, Wayne, PA, USA and ‡AstraZeneca R&D, Mölndal, Sweden

Accepted for publication 27 April 2000

SUMMARY

Background: Esomeprazole (Nexium) is a new proton pump inhibitor for the treatment of acid-related diseases.

Methods: In this double-blind crossover study, 38 patients with gastro-oesophageal reflux disease (GERD) symptoms were randomized to esomeprazole 40 and 20 mg and omeprazole 20 mg once daily for 5 days. On day 5 of each dosing period, 24-h intragastric pH and pharmacokinetic variables were measured.

Results: Thirty-six patients aged 29–58 (mean 45) years completed the study. Esomeprazole 40 and 20 mg maintained intragastric pH > 4 for (mean) 16.8 and 12.7 h, respectively, vs. 10.5 h for omepra-

zole 20 mg ($P < 0.001$ and $P < 0.01$). Twenty-four-hour median intragastric pH was significantly higher with esomeprazole 40 mg (4.9) and 20 mg (4.1) than with omeprazole 20 mg (3.6) ($P < 0.001$ and $P < 0.01$). Area under the plasma concentration–time curve (AUC) was 80% higher for esomeprazole 20 mg vs. omeprazole, while that for esomeprazole 40 mg was more than five times higher (each $P < 0.0001$). Interpatient variability in intragastric pH and AUC was less with esomeprazole than with omeprazole. Esomeprazole was well tolerated and there were no safety concerns. **Conclusions:** Esomeprazole provides more effective acid control than omeprazole, with reduced interpatient variability, thereby offering the potential for improved efficacy in acid-related diseases.

INTRODUCTION

It is well established that the aggressiveness of the gastric refluxate (as reflected in the degree of mucosal injury), along with the associated symptoms of gastro-oesophageal reflux disease (GERD), are highly pH dependent. In this regard, an intragastric acidity threshold of pH 4 serves to differentiate between aggressive and nonaggressive reflux, because a refluxate of pH < 4 not only contains active pepsin but also leads to more intense symptoms.^{1, 2} Strategies aimed at

maintaining intragastric pH above this threshold represent the key to effective management of GERD, because mucosal healing correlates directly with the proportion of the 24-h period with intragastric pH > 4.³ This relationship explains why the effective, sustained acid control provided by proton pump inhibitors leads to prompt resolution of symptoms and high rates of oesophageal healing.^{4, 5} Proton pump inhibitors have therefore emerged as the initial treatment of choice for the management of GERD, as endorsed by the recent Genval Workshop Group.⁶

Omeprazole, like other proton pump inhibitors, is a substituted benzimidazole that exists as a racemic mixture of the R- and S-isomers. Esomeprazole (Nexium; Astra Zeneca R&D, Sweden) is the S-isomer

Correspondence to: Dr T. Lind, Department of Surgery, Kärnsjukhuset, Skövde, S-541 85, Sweden.
E-mail: tore.lind@vgregion.se

of omeprazole and the first proton pump inhibitor to be developed as a single isomer for the treatment of acid-related diseases. In common with omeprazole, esomeprazole demonstrates highly effective inhibition of gastric acid secretion.⁷ Esomeprazole differs from omeprazole, however, in displaying lower first-pass hepatic metabolism and slower plasma clearance, resulting in higher plasma concentrations.⁸ The increased systemic bioavailability of esomeprazole offers the prospect of improved clinical efficacy and more effective management of acid-related diseases.

The aim of this study was to compare the acid inhibitory effects, pharmacokinetics and safety of esomeprazole and omeprazole in patients with GERD. Comparisons were performed between the recommended dosage of omeprazole (20 mg once daily) and the corresponding dosage of esomeprazole; in addition the effects of a higher esomeprazole dosage (40 mg once daily) were investigated for evidence of a dose-response relationship.

METHODS

Patients

Male and female patients with symptoms of suspected or confirmed (by investigation) GERD, aged 30–60 years, were eligible for inclusion. The main exclusion criteria were symptoms of gastrointestinal bleeding (e.g. melena, haematemesis), any pharmacotherapy for GERD within the previous 2 weeks, and previous history of oesophago-gastric surgery. Patients with a history of alcoholism or drug abuse and those with significant concomitant diseases likely to interfere with the results of the study were also excluded from enrolment. Pregnant or nursing women, and those not likely to be using adequate contraceptive measures during the course of the study, were excluded. The study was performed according to the ethical principles of the Declaration of Helsinki, and the protocol was approved by the independent Ethics Committee of the University of Gothenburg, Sweden, prior to study commencement. Informed written consent was obtained from all patients.

Study design

The study used a double-blind, randomized, crossover design, comprising three 5-day dosing periods separated

by washout intervals of at least 2 weeks. An initial screening visit comprised determination of patients' complete medical history, physical examination and measurement of laboratory safety variables, as well as a serological assessment of *Helicobacter pylori* status using routine methods. Eligible patients were randomized to receive oral therapy with esomeprazole 40 mg o.d., esomeprazole 20 mg o.d. or omeprazole 20 mg o.d. Doses were to be administered at least 30 min before breakfast. In order to maintain patient and investigator blinding, all study medication was identical in appearance and comprised enteric-coated pellets within gelatine capsules. During the washout periods, patients were allowed to use antacids as needed for relief of reflux symptoms. Concomitant treatment with H₂-receptor antagonists, prokinetic drugs or other proton pump inhibitors was not permitted during the study.

Measurement of intragastric pH

After an overnight fast, patients returned to the clinic on day 5 of each dosing period. Study medication was administered under the supervision of the investigator, after which 24-h intragastric pH was recorded using a microelectrode (Ingold bipolar glass; Mettler-Toledo GmbH, Switzerland) linked to a Digitrapper MK III recorder (Synectics AB, Sweden). The electrode was inserted transnasally and positioned about 10 cm below the lower oesophageal sphincter. Patients were mobile throughout the recording, and were instructed not to lie down for periods longer than 10 min during the day. Data were analysed using EsopHogram software (Synectics AB, Sweden) to calculate the percentage of the 24-h period for which intragastric pH exceeded 4, along with 24-h median intragastric pH. To ensure consistency of results, food and beverage intake was standardized throughout each day of intragastric pH measurement for all patients.

Pharmacokinetics

Venous blood samples were drawn at regular intervals up to 8 h after drug administration for pharmacokinetic determinations on day 5 of each dosing period. Plasma concentrations of esomeprazole and omeprazole were measured using normal-phase liquid chromatography and ultra-violet detection, as previously described.⁹ The following pharmacokinetic variables were determined: area under the plasma concentration-time curve

(*AUC*); maximum plasma concentration (C_{\max}); terminal half-life ($t_{1/2\lambda z}$); and time to C_{\max} (t_{\max}). *AUC* was determined using the log-linear trapezoidal method (the residual area after the last data point was calculated as $C_{\text{last}}/\lambda z$, where C_{last} is the concentration at the last measurable data point and λz the terminal slope of the plasma concentration–time profile). $t_{1/2\lambda z}$ was calculated as $\ln 2/\lambda z$, while t_{\max} was determined from the plasma concentration–time profile.

Safety and tolerability

All adverse events spontaneously reported, as well as those elicited by open questioning or observed by the investigator, were recorded. Routine laboratory safety variables, including blood and urine analysis, were assessed before and at the end of the study (2–5 days after completion of the last dosing period). Clinically significant changes in laboratory variables were followed up for as long as medically necessary.

Statistical analysis

Differences between treatment groups in 24-h median intragastric pH, the duration for which intragastric pH was > 4 and *AUC* were analysed using a mixed-model analysis of variance, with fixed effects for period, carry-over and treatment and a random effect for patients. Estimated means and treatment differences, together with 95% confidence intervals, were calculated. *AUC* values were log-transformed before the analysis. The results for *AUC* were then calculated by taking the exponential of the estimates, and are presented as geometric means together with 95% confidence intervals.

RESULTS

A total of 36 of 38 enrolled patients completed the study. One discontinuation was due to nonattendance, and another patient withdrew from the study as a result of an adverse event (tiredness) during a washout interval. Baseline demographic and clinical characteristics of the patients completing the study are shown in Table 1. All patients were Caucasian, and the majority (83%) were *H. pylori*-negative. About one-third of patients were smokers.

Counting of returned study medication indicated 100% compliance during each active dosing period. No patient received concomitant medication during the study that was deemed likely to have affected the pharmacodynamic or pharmacokinetic findings.

Intragastric pH

The intragastric pH–time profiles following oral administration of esomeprazole and omeprazole are shown in Figure 1. For both dosages of esomeprazole the percent-

Table 1. Baseline demographics and clinical characteristics of evaluable patients ($n = 36$)

Gender, male : female (%)	42 : 58
Mean age, years (range)	45 (29–58)
Mean bodyweight, kg (range)	80 (46–108)
Positive <i>H. pylori</i> status (no. of patients)*	6 (17%)
Smokers (no. of patients)	13 (36%)
Duration of GERD (no. of patients)	
1–5 years	9
> 5 years	27

* As determined by serology.




Figure 1. Twenty-four-hour median intragastric pH–time profiles after 5 days' dosing with esomeprazole (40 and 20 mg once daily) and omeprazole (20 mg once daily) in 36 patients with symptoms of gastro-oesophageal reflux disease; arrows indicate timepoints at which standardized meals were served.

Variable	Treatment group*		
	Esomeprazole 40 mg	Esomeprazole 20 mg	Omeprazole 20 mg
Mean duration (hours) with intragastric pH > 4 (95% CI)	16.8 (15.0–18.4)‡	12.7 (11.0–14.4)†	10.5 (8.8–12.2)
Mean percentage of 24-h period with intragastric pH > 4 (95% CI)	69.8 (62.3–76.8)‡	53.0 (46.0–60.0)†	43.7 (36.7–50.7)
24-h median intragastric pH (95% CI)	4.9 (4.5–5.2)‡	4.1 (3.8–4.5)†	3.6 (3.2–3.9)

* All doses given once daily.
CI, confidence interval; † $P < 0.01$ vs. omeprazole; ‡ $P < 0.001$ vs. omeprazole and esomeprazole 20 mg.

age of the 24-h period for which intragastric pH remained > 4 was significantly higher compared with omeprazole (Table 2). Thus, esomeprazole 40 mg maintained intragastric pH > 4 for about 6 h longer than omeprazole 20 mg (16.8 h vs. 10.5 h). This difference was about 2 h for esomeprazole 20 mg vs. omeprazole 20 mg (12.7 vs. 10.5 h, respectively). As a result, mean 24-h median intragastric pH was significantly higher for each dosage of esomeprazole compared with omeprazole. Furthermore, esomeprazole 40 mg was significantly more effective than the 20 mg dosage in terms of the pharmacodynamic response. The esomeprazole 40 mg dosage also produced less interpatient variability (as expressed by standard deviation) in the percentage of time for which intragastric acidity exceeded pH 4 (17.8%), compared with values of 19.7% and 22.8%, respectively, for esomeprazole 20 mg and omeprazole 20 mg.

In terms of individual patient responses, an intragastric pH > 4 was maintained for more than 12 h in 92%, 54% and 44% of patients receiving esomeprazole 40 mg, esomeprazole 20 mg and omeprazole 20 mg, respectively, and an intragastric pH > 4 was maintained for more than 16 h in 56%, 24% and 14% of patients, respectively (Figure 2).

A total of six patients were *H. pylori*-positive. In this patient sub-group there was no clinically relevant difference between the pharmacodynamic response to esomeprazole and omeprazole (data not shown).

Pharmacokinetics

Pharmacokinetic variables after 5 days' dosing with esomeprazole or omeprazole are summarized in Table 3. AUC following dosing with esomeprazole 20 mg was approximately 80% higher than with omeprazole 20 mg;

Table 2. Effect of 5 days' dosing with esomeprazole or omeprazole on intragastric acidity in 36 patients with symptoms of gastro-oesophageal reflux disease










	Percentage patients with intragastric pH above 4		
	for at least 8 hrs	for at least 12 hrs	for at least 16 hrs
Omeprazole 20 mg	67% 	45% 	14% 
Esomeprazole 20 mg	76% 	54% 	24% 
Esomeprazole 40 mg	97% 	92% 	56% 

Figure 2. Percentage of patients maintaining intragastric pH > 4 for at least 8, 12 and 16 h after 5 days' dosing with esomeprazole (40 and 20 mg once daily) and omeprazole (20 mg once daily).

Table 3. Pharmacokinetic variables after 5 days' dosing with esomeprazole or omeprazole in 36 patients with symptoms of gastro-oesophageal reflux disease

Variable	Treatment group*		
	Esomeprazole 40 mg	Esomeprazole 20 mg	Omeprazole 20 mg
Geometric mean AUC , $\mu\text{mol} \cdot \text{h/L}$ (95% CI)	12.64 (9.89–16.17)	4.18 (3.27–5.35)	2.34 (1.83–3.00)
Median C_{max} , $\mu\text{mol/L}$ (range)	5.13 (1.59–9.61)	2.42 (0.51–4.78)	1.41 (0.15–3.51)
Median $t_{1/2\alpha}$, h (range)	1.6 (0.8–2.9)	1.3 (0.5–2.5)	1.0 (0.3–2.8)
Median t_{max} , h (range)	1.2 (1.0–4.0)	1.0 (0.5–8.0)	1.0 (0.5–6.0)

* All doses given once daily.

AUC , area under the plasma concentration–time curve; CI, confidence interval; C_{max} , maximum plasma concentration; $t_{1/2\alpha}$, terminal half-life; t_{max} , time to C_{max} .

for esomeprazole 40 mg, AUC was over five times higher vs. omeprazole. These differences were statistically significant (each $P < 0.0001$). Interpatient variability (standard deviation, based on log-transformed values) in AUC was less with esomeprazole 40 mg (0.47) and 20 mg (0.64) than with omeprazole (0.73).

Mean plasma concentration–time profiles for esomeprazole 40 and 20 mg and omeprazole are shown in Figure 3. Overall, C_{max} values for each dosage of esomeprazole were higher than those observed for omeprazole (Figure 3 and Table 3), although t_{max} values were similar (median ~ 1 h) for all treatments. Plasma $t_{1/2\alpha}$ values tended to be somewhat longer for esomeprazole (median 1.3 and 1.6 h) than for omeprazole (median 1.0 h) (Table 3).

Safety and tolerability

Both dosages of esomeprazole were well tolerated, and the profile and incidence of adverse events were similar

to that observed with omeprazole 20 mg. The most commonly reported adverse events were gastrointestinal complaints (e.g. abdominal pain, nausea, diarrhoea), respiratory infection and headache. Such adverse events were typically mild and did not necessitate drug discontinuation. No serious adverse events occurred during, or as a result of, treatment and there were no clinically relevant changes in laboratory safety variables.

DISCUSSION

Frequent and prolonged oesophageal exposure to gastric refluxate is pivotal to the pathogenesis of GERD. Indeed, the degree of mucosal injury,³ the frequency of reflux symptoms¹⁰ and the severity of oesophageal pain² in GERD are functions of oesophageal acid exposure (i.e. duration of exposure and pH of the refluxate). Among the various intragastric acidity thresholds that have been proposed to differentiate between aggressive and nonaggressive reflux, pH 4 appears optimal.¹ Consequently, maintenance of an intragastric pH above 4 for the greater part of each 24-h period is crucial for ensuring oesophageal healing and symptom relief in GERD.

Using this intragastric pH threshold, our findings show that esomeprazole achieves significantly greater acid control than omeprazole. Thus, esomeprazole increased the duration for which intragastric pH exceeded 4 and achieved a higher median intragastric pH across the entire 24-h period. These benefits were found with each dosage of esomeprazole (40 and 20 mg), although they were more pronounced with the 40 mg dosage. Indeed, the pharmacodynamic effect of esomeprazole 40 mg was significantly greater than that observed for the lower dosage. In view of this it would be pertinent to




Figure 3. Mean plasma concentration–time profiles after 5 days' dosing with esomeprazole (40 and 20 mg once daily) and omeprazole (20 mg once daily) in 36 patients with symptoms of gastro-oesophageal reflux disease.

assess the performance of esomeprazole 40 mg against omeprazole 40 mg. These findings can be explained by the increased *AUC* values for the higher dosage relative to both esomeprazole 20 mg and omeprazole (see Table 2). Potentially, higher *AUC* values for esomeprazole lead to increased delivery of the drug to the canalicular lumen of the parietal cell and hence more pronounced inhibition of acid secretion, in accordance with the association between the *AUC* value of omeprazole and its antisecretory effect.¹¹ Coupled with reduced interpatient variability in pharmacodynamic response, these properties of esomeprazole may contribute towards improved clinical efficacy over omeprazole.

Several studies have previously reported the effect of omeprazole on 24-h intragastric pH.^{3, 12, 13} At a dosage of 20 mg, for example, omeprazole raised intragastric pH to > 4 for about 60% of the 24-h interval in patients with GERD,³ whereas Blum and colleagues¹³ reported a mean value of 51% in healthy volunteers. Although the present study suggests a less pronounced acid suppressant effect for omeprazole 20 mg, this may be explained by different approaches to the way in which intragastric pH was measured and the disposition of food intake during the monitoring period. Indeed, a study in healthy volunteers found that omeprazole 20 mg maintained intragastric pH > 4 for about 40% of the 24-h interval,¹⁴ which is similar to the mean value reported in the present study (44%). Current *H. pylori* status may also have affected the results of such studies. In the present study, for example, intragastric pH tended to remain > pH 4 for a longer period of time for both esomeprazole and omeprazole among *H. pylori*-positive patients, although the small number of patients precluded a formal statistical analysis of such findings.

As previously reported for omeprazole,^{15, 16} esomeprazole showed nonlinear pharmacokinetics. Thus, doubling the dosage of esomeprazole led to a 3-fold increase in *AUC*. In addition, the *AUC* of esomeprazole 20 mg was approaching double that of the same dosage of omeprazole. Although such findings are limited by the fact that we evaluated only two dosages of esomeprazole, the results suggest that the increased *AUC* of esomeprazole relative to omeprazole is attributable to differences in the rate of elimination. Such differences may explain the enhancement of acid control with esomeprazole compared with omeprazole, as previously discussed. Interestingly, esomeprazole showed less interpatient variability in *AUC* than

omeprazole. Ultimately, this profile of esomeprazole may contribute to increased predictability of the therapeutic response in patients with acid-related disorders such as GERD.

While we did not perform symptomatic assessments or endoscopic determinations of oesophageal healing in the present study, our preliminary findings for esomeprazole have potentially important implications for the treatment of patients with GERD. Indeed, patients with GERD can experience reflux of gastric contents into the oesophagus at any time, which underscores the need to provide sustained control of intragastric acidity throughout the 24-h period to alleviate symptoms. Using the threshold level of intragastric pH > 4, esomeprazole 40 mg achieved control of intragastric acidity for 70% of the 24-h period, compared with 44% for omeprazole 20 mg. Thus, the increased duration with intragastric pH > 4 observed during esomeprazole therapy may translate into improved symptom control in GERD and other acid-related diseases compared with omeprazole. In addition, enhanced acid control with esomeprazole has implications for the rate of oesophageal healing. Like symptoms, there is correlation between the rate of healing of oesophagitis in patients with GERD and the duration for which intragastric pH is maintained above pH 4.³ The increased duration with intragastric pH > 4 observed during esomeprazole therapy may therefore lead to increased rates of oesophageal healing compared with omeprazole. Moreover, predictability of healing is likely to be increased, relative to omeprazole, in view of the fact that interpatient variability in the pharmacodynamic response is less for esomeprazole than for omeprazole. Further comparative studies are required to determine the clinical efficacy, in terms of symptom control and rate of healing, of esomeprazole in GERD and other acid-related diseases.

In conclusion, esomeprazole is well tolerated and demonstrates significantly superior acid control compared to omeprazole, combined with reduced interpatient variability. Taken together, these findings suggest that esomeprazole offers the potential for improved clinical efficacy in patients with GERD and other acid-related diseases.

ACKNOWLEDGEMENTS

This study was sponsored by AstraZeneca R&D, Mölnådal, Sweden.

REFERENCES

- 1 Hunt RH. Importance of pH control in the management of GERD. *Arch Intern Med* 1999; 159: 649–57.
- 2 Smith JL, Operkun AR, Larkai E, Graham DY. Sensitivity of oesophageal mucosa to pH in gastro-oesophageal reflux disease. *Gastroenterology* 1989; 96: 683–9.
- 3 Bell NJV, Burget D, Howden CW, Wilkinson J, Hunt RH. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. *Digestion* 1992; 51(Suppl. 1): 59–67.
- 4 Chiba N. Proton pump inhibitors in acute healing and maintenance of erosive or worse esophagitis: a systematic overview. *Can J Gastroenterol* 1997; 11(Suppl. B): 66B–73B.
- 5 Chiba N, de Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. *Gastroenterology* 1997; 112: 1798–810.
- 6 Dent J, Brun J, Fendrick AM, *et al.* on behalf of the Genval Workshop Group. An evidence-based appraisal of reflux disease management—the Genval Workshop Report. *Gut* 1999; 44(Suppl. 2): S1–S16.
- 7 Andersson T, Röhss K, Hassan-Alin M, Bredberg E. *Pharmacokinetics and dose-response relationship of esomeprazole (abstract)*. *Gastroenterology* 2000; 118: A1210.
- 8 Hassan-Alin M, Röhss K, Andersson T, Nyman L. *Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects (abstract)*. *Gastroenterology* 2000; 118: A16.
- 9 Lagerström PO, Persson BA. Determination of omeprazole and metabolites in plasma and urine by liquid chromatography. *J Chromatogr* 1984; 309: 347–56.
- 10 Joelsson B, Johnsson F. Heartburn—the acid test. *Gut* 1989; 30: 1523–5.
- 11 Lind T, Cederberg C, Ekenved G, Haglund U, Olbe L. Effect of omeprazole—a gastric proton pump inhibitor—on pentagastrin stimulated acid secretion in man. *Gut* 1983; 24: 270–6.
- 12 Houben GM, Hooi J, Hameeteman W, Stockbrügger RW. Twenty-four-hour intragastric acidity: 300 mg ranitidine b.d., 20 mg omeprazole o.m., 40 mg omeprazole o.m. vs. placebo. *Aliment Pharmacol Ther* 1995; 9: 649–54.
- 13 Blum RA, Shi H, Karol MD, Greski-Rose PA, Hunt RH. The comparative effects of lansoprazole, omeprazole, and ranitidine in suppressing gastric acid secretion. *Clin Ther* 1997; 19: 1013–23.
- 14 Takeda H, Hokari K, Asaka M. Evaluation of the effect of lansoprazole in suppressing acid secretion using 24-hour intragastric pH monitoring. *J Clin Gastroenterol* 1995; 20(Suppl. 1): S7–S9.
- 15 Howden CW. Clinical pharmacology of omeprazole. *Clin Pharmacokinet* 1991; 20: 38–49.
- 16 Andersson T, Cederberg C, Heggelund A, Lundborg P. The pharmacokinetics of single and repeated once-daily doses of 10, 20 and 40 mg omeprazole as enteric-coated granules. *Drug Invest* 1991; 3: 45–52.